echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Biology JS007 injection was approved for clinical use

    Junshi Biology JS007 injection was approved for clinical use

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Today, Junshi Biopharmaceuticals announced that the company received the "Notice of Drug Clinical Trial Approval" issued by the National Medical Products Administration, and the clinical trial application for JS007 injection (project code "JS007") was approved.

    It is reported that JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection independently developed by the company, which is mainly used for the treatment of advanced malignant tumors.
    Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is an important receptor on the surface of T cells to regulate immune responses.
    JS007 can specifically bind to CTLA-4 and effectively block the interaction between CTLA-4 and its ligand B7 (CD80 or CD86), thereby activating T lymphocytes and inhibiting tumor growth.
    At present, the same target foreign drug ipilimumab, as the first immune checkpoint inhibitor, has been proven to be significant in multiple tumor types such as melanoma, lymphoma, renal cell carcinoma, urothelial cancer, ovarian cancer, and non-small cell lung cancer.
    The anti-tumor effect of the drug, and was approved for the treatment of advanced melanoma.
    Pre-clinical research data show that JS007 has similar safety compared to ipilimumab, which has the same target but has a different sequence, but has better efficacy.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.